Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Up 21.3% in February

Posted by Donald Scott on Mar 8th, 2025

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) saw a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 110,900 shares, a growth of 21.3% from the January 31st total of 91,400 shares. Based on an average daily trading volume, of 78,800 shares, the short-interest ratio is presently 1.4 days. Currently, 2.5% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Brainstorm Cell Therapeutics in a research note on Sunday, March 2nd. They set a “hold” rating on the stock.

Get Our Latest Stock Analysis on Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Stock Up 3.8 %

NASDAQ:BCLI opened at $1.65 on Friday. The stock’s 50 day moving average price is $1.92 and its 200 day moving average price is $2.39. The company has a market capitalization of $9.41 million, a PE ratio of -0.34 and a beta of 0.26. Brainstorm Cell Therapeutics has a 52-week low of $1.05 and a 52-week high of $11.89.

Brainstorm Cell Therapeutics Company Profile

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.